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Abstract Loco-regional control rate of nasopharyngeal
carcinoma (NPC) has improved signiWcantly in the past
decade. However, local recurrence still represents a major
cause of mortality and morbidity in advanced stages, and
management of local failure remains a challenging issue in
NPC. The best salvage treatment for local recurrent NPC
remains to be determined. The options include brachyther-
apy, external radiotherapy, stereotactic radiosurgery, and
nasopharyngectomy, either alone or in diVerent combina-
tions. In this article we will discuss the diVerent options for
salvage of locally recurrent NPC. Retreatment of locally
recurrent NPC using radiotherapy, alone or in combination
with other treatment modalities, as well as surgery, can
result in long-term local control and survival in a substan-
tial proportion of patients. For small-volume recurrent
tumors (T1–T2) treated with external radiotherapy, brachy-
therapy or stereotactic radiosurgery, comparable results to
those obtained with surgery have been reported. In contrast,
treatment results of advanced-stage locally recurrent NPC
are generally more satisfactory with surgery (with or with-
out postoperative radiotherapy) than with reirradiation.
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Introduction
Loco-regional control rate of nasopharyngeal carcinoma
(NPC) has improved signiWcantly in the past decade due to
the advances in imaging, radiotherapy techniques, and the
use of combined treatments with chemoradiotherapy. At
present, the reported 5-year local control rates of NPC
ranges from 80 to 85%. Despite the improved outcome in
local control, local recurrence still represents a major cause
of mortality and morbidity in advanced stages, and manage-
ment of local failure remains a challenging issue in NPC.
Diagnosis of recurrence
Early detection of persistent or recurrent disease is of para-
mount importance. The most frequently used methods
include image techniques [computed tomography (CT),
magnetic resonance imaging (MRI)], rigid nasopharyngeal
endoscopy and nasopharyngeal biopsies, and serological
tests for immunoglobulin A against Epstein–Barr virus
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(EBV). For patients with elevated anti-EBV titers or suspi-
cious endoscopic examination, a biopsy of the nasopharynx
is then indicated to detect the recurrence in its early stages.
Rigid endoscopic examination provides a better view than
Xexible endoscopy, to the extent that even submucosal
bulges can be seen. CT and MRI are performed on patients
with a conWrmed diagnosis. CT scan delineates the extent
of tumor in the nasopharynx and whether it has aVected sur-
rounding bony structures. MRI, aside from providing better
images of soft tissue, also shows tumor size and extension
to the skull base and intracranial cavity. Initial assessment
is better carried out by rigid nasopharyngeal endoscopy;
according to prospective trials comparing it to CT shows a
signiWcantly better agreement with the histological Wndings
[1, 2].
A paraneoplastic syndrome (PNS) often represents the
only signal of a silent neoplasm and sometimes it precedes
the tumor itself. PNS may precede the clinical manifestation
of a persistent or recurrent NPC or of asymptomatic metasta-
ses. PNS subsides in parallel to response of the NPC, and
thus may be useful for the diagnosis of recurrence. These
syndromes can follow the clinical course of the tumor and
thus can be useful for monitoring its evolution [3].
In addition to the most frequent local recurrences, treat-
ment failures can be observed in the neck. The detection of
the cervical lymph node metastases on presentation has
improved with MRI and positron emission tomography
(PET), and can be cytologically conWrmed through Wne
needle aspiration cytology.
In a series of 891 patients with recurrent NPC, only 70%
of patients had local failure alone, as 25% also suVered
from regional relapse and 8% from distant metastasis [4].
If the tumor recurs or persists in the nasopharynx after
radiotherapy, then salvage procedures are still an option if
there is no distant metastasis. In the next sections we will
discuss the diVerent options for salvage of recurrent NPC.
Due to the signiWcantly better local control and survival
rates for patients with persistent disease [5], only local
recurrent tumors will be considered.
External beam radiotherapy
Results of retreatment and inXuencing factors
Despite radical irradiation, local recurrence remains a
major problem for patients with NPC. The reported inci-
dence varies from 8 to 58%, with the median at 34% [4].
Locally persistent or recurrent NPC may be due to the
intrinsic radio-resistance of the primary tumor, insuYcient
dose, or a geographic miss during the initial radiotherapy.
The results of initial treatment with radiation therapy have
improved over the years due to the advances in diagnostic
imaging, which help to localize the full extent of the primary
tumor, the higher tumor doses delivered [6], the diVerent
regimes of fractionation, the use of advanced radiation
delivery techniques, such as intensity-modulated radiation
therapy (IMRT) [7–9], and the use of concomitant chemo-
therapy [10].
Pretreatment evaluation of the extent of disease, includ-
ing paranasopharyngeal extension, is crucial. Early detec-
tion is important as the chance of salvage varies with the
extensiveness of local recurrence. In the series of Lee et al.
[4] the 5-year local control rate for rT3 patients was only
11% compared to 35 and 28% for rT1 and rT2, respectively,
which also translated into worse overall survival for rT3
patients (4%) as compared to for rT1 (27%). In Wang’s
series [11], the 5-year survival was 38% for patients with
rT1–T2 tumors and 15% for those patients with rT3–T4.
Overall 5-year actuarial local control, and overall survival
rank from 15 to 35%, and 8 to 41%, respectively [4, 11–14].
These results emphasize the importance of close follow-
up after primary treatment and more vigorous attempts for
early detection of local recurrence by rigid nasopharyngeal
endoscopy [15], CT and/or MRI. Recent studies indicate
that PET using 18-Xuoro-2-deoxyglucose (FDG), is more
accurate in detecting local recurrence after curative
(chemo) radiation than MRI [16, 17] and/or may add useful
additional information to disputable Wndings on MRI [18,
19]. Nevertheless, we must consider the diYculty in imag-
ing near the brain, which is always hypermetabolic, and the
diYculties with local inXammation secondary to otitis
media and bony necrosis of the skull base related to radiation.
In some reports there is a polarization of primary radio-
therapy and reirradiation into two extremes (good results in
primary treatment and poor results in reirradiation, and
viceversa) which is most likely due to the successful pre-
vention of avoidable local failures during primary radio-
therapy and the natural selection of the most radioresistant
tumors for reirradiation [14].
It is of interest to remark that although patients with
undiVerentiated carcinomas have a notably higher 5-year
survival than those with squamous cell carcinomas, in some
series there is no diVerence when considering 10-year sur-
vival [12]. This longer survival may be due to slower
regrowth of undiVerentiated carcinomas, evident in their
longer time to local recurrence, as well as that patients with
undiVerentiated carcinomas are more likely to develop late
distant metastases. The stage at which recurrence is diag-
nosed is the most signiWcant prognostic factor, but lesions
involving the skull base should be diVerentiated from other
advanced-stage tumors when evaluating tumor control or
survival [20, 21].
Furthermore, patients without evidence of intracranial
invasion or cranial nerve palsy have better survival than
those with such lesions (3-year survival, 31 vs. 4%) [20].Eur Arch Otorhinolaryngol (2010) 267:1811–1824 1813
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Other factors adversely aVecting survival are the simulta-
neous presence of neck metastases and patients whose tumor
recurred at 1–2 years or less after initial treatment [11, 22].
Irrespective of the total dose given during initial treat-
ment, there is signiWcant correlation between the dose at
reirradiation and the salvage rate. The highest local control
rates have been achieved with a total dose of at least 60 Gy
[4, 11, 14, 20].
Nevertheless, data from retrospective studies must be
interpreted cautiously when comparing treatment tech-
niques because unrecognized factors may have been used to
select the type of treatment.
Complications of retreatment
DiVerent kinds of complications have been reported in
patients undergoing reirradiation, ranging from 6 to 85%
[4,  11,  13,  14,  20,  22]. This enormous range can be
explained by the diVerent reirradiation doses and tech-
niques used as well as by the fact that some authors only
report severe complications. The most frequent complica-
tions include xerostomia, trismus, sensorineural hearing
loss, and middle ear eVusion, but also brain necrosis which
has been reported up to 20% of patients [4, 11, 13, 14, 20,
22]. Fatal complication rates between 2 and 10% have also
been reported [4, 12, 14, 23]. The incidence of severe com-
plications depends on the dose received and treatment
modality. Patients who were retreated with a cumulative
external beam dose >100 Gy had a high incidence of severe
complications: 4% for patients receiving doses less than or
equal to 100 Gy compared with 39% for those patients who
received doses greater than 100 Gy [12]. Lee et al. [24]
reported on the largest series of 654 local recurrent NPC
patients treated with reirradiation. In their series, the risk of
late complications was predominantly aVected by the bio-
logical eVective dose of the primary treatment, while the
corresponding impact of reirradiation failed to reach statis-
tical signiWcance, indicating higher tolerance for reirradia-
tion when primary treatment has been carried out with
better sparing of normal tissues.
External reirradiation of NPC with curative intent is
often diYcult due to the large number of nearby critical
structures that were previously irradiated to a high dose.
Conventional external radiotherapy delivered by a 10-MV
photon beam with bilateral opposing Welds to cover the
recurrent tumor site and margins yields a higher complica-
tions rate than three-dimensional (3D) conformal radiother-
apy or IMRT, which try to radiate the previously radiated
areas (such as temporal lobes, temporo-mandibular joints
and middle ears) at less than 60% of the prescribed dose.
Thus, Chang et al. [20] observed severe complications in
23% of the conventional radiotherapy group, but only in
9% of the conformal radiotherapy group. Furthermore, with
conventional external radiotherapy, 13 patients (14%) were
found to have brain necrosis, and no brain necrosis
occurred in patients treated with conformal radiotherapy,
although the lower incidence of complications they saw in
patients treated with conformal radiotherapy may also be
explained by a shorter follow-up [20].
For patients with extensive disease requiring external
radiotherapy, superior dose distribution and organ sparing
have been demonstrated with IMRT over more conven-
tional conformal radiation delivery techniques for salvage
of NPC. Excellent local control rates have been reported
using IMRT for newly diagnosed NPC [25,  26], but
although Lu et al. [27] have reported good local control rate
after high-dose IMRT (68–70 Gy) for recurrent NPC, the
relatively short follow-up makes it diYcult to evaluate late
toxicities in their patients. Late toxicities are still common
after IMRT, although generally most are mild. Neurologi-
cal toxicity represents the main complication but it appears
to be less frequent than after conventional two-dimensional
(2D) or 3D conformal reirradiation [28]. Longer follow-up
of patients is still needed to address more clearly the inci-
dence and impact of late toxicities.
Brachytherapy
What is the best salvage treatment for early-stage recurrent
NPC? It is an unanswered question. The options include
brachytherapy alone with either interstitial or intracavitary
approach, external radiotherapy with/without brachyther-
apy, stereotactic radiosurgery, and nasopharyngectomy.
The last two options will be developed in other sections.
The inherent physical and dosimetric characteristics of
brachytherapy allow the delivery of a high dose to the naso-
pharynx while minimizing the dose to the adjacent structures.
For small-volume recurrences treated with brachyther-
apy alone, Choy et al. [29] reported a local control rate of
61% at 5 years with 60 Gy delivered by gold grain
implants. Moreover, the local control was superior in fail-
ures conWned to the nasopharynx compared to failures
extending beyond the nasopharynx, 81 versus 44%, respec-
tively. Similar results have been observed by Kwong et al.
[5] who observed an overall survival rate at 5 years of 54%,
with the sequelae of headache, palatal Wstula, and mucosal
radiation necrosis at the site of implantation in 28, 19, and
16% of the patients, respectively.
Patients with large volume local recurrence will beneWt
from external radiotherapy with or without brachytherapy.
Taking into account that a small increase in external radio-
therapy dose may result in marked increase in toxicity, for
rT1–T2 local recurrences combined treatment is recom-
mended as shown by its superior local control and rela-
tively lower risk of complications. With the advances in1814 Eur Arch Otorhinolaryngol (2010) 267:1811–1824
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imaging technology and the advent of 3D conformal tech-
niques, it is possible to reduce the target volume without
jeopardizing the local control, and the complication rates
should be reduced. After the completion of external radio-
therapy, a routine brachytherapy boost can improve the
local control of patients with T1–T2 disease. However,
treatment results of advanced-stage locally recurrent NPC
has been unsatisfactory either with external radiotherapy or
brachytherapy, alone or combined [24].
Thus, Leung et al. [23] compared the results of external
radiotherapy alone and combined with brachytherapy. Sub-
group analysis on the external radiotherapy and combined
treatment groups showed a 3-year local failure-free survival
rate of 33 and 57%, respectively, but external radiotherapy
group had an excess of patients with rT3 disease. Further
analysis was performed on the rT1–T2 patients showing a
trend toward improvement in local control in favor of the
combined treatment group (3-year local failure-free survival
rate of 72% with combined treatment; 54% with external
radiotherapy). Multivariate analyses showed that rT stage
and total equivalent dose were signiWcant predicting factors
of success. Concerning major and central nervous system
complications, modality of treatment (more complications
with external radiotherapy group) and rT stage were signiW-
cant for predicting the occurrence of such complications [23].
On the other hand, Zheng et al. [30] reported that the 5-
year actuarial local failure-free survival rate of patients
with initially diagnosed T3–T4 disease for the 3D confor-
mal radiotherapy group and brachytherapy group was 84
versus 60%, with 3D conformal radiotherapy providing bet-
ter local control than brachytherapy as a salvage treatment
for locally persistent NPC, especially in patients with ini-
tially diagnosed T3–T4 disease.
These results highlight the importance of early detection
of local recurrences. The primary inXuence is a factor inde-
pendently signiWcant after adjustment for rT-stage eVect. In
the Leung et al. [23] series, 65% of rT3 recurrence origi-
nated from a T3 primary.
The possibility of adopting other approaches, such as
concurrent chemoradiation or accelerated fractionation,
which have been shown to improve the treatment outcome
in the primary treatment of T3–T4 disease, should be seri-
ously considered.
Stereotactic radiosurgery
Fundamentals and results of treatment
Because of the poor results of conventional external reirra-
diation, other techniques of reirradiation have been
employed for locally recurrent NPC, such as stereotactic
radiosurgery. Stereotactic radiosurgery is a highly precise
form of radiation therapy used primarily to treat tumors and
other abnormalities of the brain. Despite its name, stereo-
tactic radiosurgery is a non-surgical procedure that delivers
a single high dose of precisely targeted radiation using
highly focused gamma-ray or X-ray beams that converge
on the speciWc area or areas of the brain where the tumor or
other abnormality resides, minimizing the amount of radia-
tion to healthy brain tissue. Although stereotactic radiosur-
gery is often completed in a 1-day session, sometimes
fractionated stereotactic treatment is applied, especially for
larger tumors. This procedure is usually referred to as frac-
tionated stereotactic radiotherapy in case more than Wve
fractions are given.
Several series have reported satisfactory local control
when stereotactic radiosurgery was used to treat recurrent
NPC, as shown by Chua et al. [31] who reported a 5-year
overall survival rate of 47%. The time interval from pri-
mary radiotherapy, rT stage, prior local failures and tumor
volume were signiWcant predictive factors for local control
and/or survival. A radiosurgery prognostic scoring system
was designed based on these predictive factors. Five-year
local failure-free probabilities in patients with good, inter-
mediate and poor prognostic scores were 100, 42.5, and
9.6%, respectively. The corresponding 5-year overall sur-
vival rates were 100, 51.1, and 0% [31].
It has been postulated that, combining stereotactic radio-
surgery with high-dose-rate brachytherapy might improve
the survival because the single large dose of radiosurgery
may increase tumor cell kill overcoming the inherent radiore-
sistance of cells. Low et al. [32] treated 36 patients with local
recurrent NPC in stage rT1–T2 with a schedule of 18 Gy fol-
lowed by two separate fractions of 6 Gy each by intracavitary
brachytherapy. The actuarial 5-year disease-free survival and
overall survival were 57% (78% for rT1, and 39% for rT2)
and 62% (80% for rT1, and 48% for rT2), respectively. How-
ever, 44% of patients had late complications, including cra-
nial nerve palsies (20%), temporal lobe necrosis (8%), and
osteoradionecrosis of the skull base (17%).
A matched cohort study to select patients with similar
characteristics treated by stereotactic radiosurgery (median
dose 12.5 Gy) or intracavitary irradiation (total dose of
60 Gy) was carried out by Chua et al. [33] in 74 patients
with local NPC failure, generally at stage rT1–T2. The 3-
year local failure-free rate was 78% for the radioactive gold
grain group compared with 68% for the stereotactic radio-
surgery group, whereas the overall survival rate was better
in the stereotactic radiosurgery group (3-year survival rate
of 77 vs. 66%), but in both circumstances the diVerences
were not statistically signiWcant. Furthermore, when the
impact of tumor volume on treatment outcome was
adjusted, no diVerence in tumor control was observed
between the two groups, suggesting that both salvage treat-
ments have comparable eYcacy. The incidence of compli-Eur Arch Otorhinolaryngol (2010) 267:1811–1824 1815
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cations was similar in number in both groups, but
complications in the stereotactic radiosurgery group were
more severe (21.6% of neuroendocrine complications, 13%
of brain necrosis, 5% of cranial neuropathy, 5% of pituitary
insuYciency, and severe hemorrhage from a carotid artery
aneurysm in one patient versus 30% of headaches, 16% of
palatal Wstula, and 13% of neuroendocrine complications in
the brachytherapy group) [33]. We can ask ourselves if we
are making any progress with the new and more sophisti-
cated procedures.
Stereotactic radiosurgery has also been used as a boost
after reirradiation with external beam for recurrent NPC
with an overall 5-year survival rate of 31% [34].
Complications of treatment
Severe complications commonly reported after stereotactic
radiosurgery for NPC include massive epistaxis, nasopha-
ryngeal necrosis, cranial nerve palsies, temporal lobe
necrosis, and osteoradionecrosis of skull base. The rela-
tively high risk of severe late complications indicates that
careful patient selection and treatment planning are
required. Severe complications were also reported by
Kocher et al. [35], who treated 8 patients with recurrent
NPC by stereotactic radiosurgery. In Kocher’s series, 3
patients died of carotid or cerebral hemorrhage after stereo-
tactic radiosurgery using a dose of 15–24 Gy, 2 patients
developed cerebral edema in temporal lobes, and 1 devel-
oped cranial neuropathy. A fatal carotid artery hemorrhage
also was the cause of dead of 33% of patients with recurrent
NPC treated with fractionated stereotactic radiotherapy
[36]. Tumors involving the Rosenmueller’s fossa and
invading deeply to the foramen lacerum are the most
important predisposing factor in fatal hemorrhage [36]. It
should be noted that the large doses per fraction used in
most series on stereotactic radiosurgery may cause these
relatively high rates of late complications [24].
As previously mentioned, fractionated stereotactic radio-
therapy is a modiWcation of stereotactic radiosurgery, which
enables fractionated irradiation to be given without losing the
advantage of the mechanical precision and accuracy as well
as dose conformity of stereotactic radiosurgery. Compared
with stereotactic radiosurgery using single fraction of high-
dose irradiation, fractionated stereotactic radiotherapy may
be superior in terms of tumor control and protection of nor-
mal tissues and organs surrounding the target.
Based on these principles, 56 patients with recurrent
NPC (rT1–T2, 38; rT3, 18) received fractionated stereotac-
tic radiotherapy. The median fractionated stereotactic
radiotherapy dose was 48 Gy in six fractions. Three-year
local failure-free survival, disease-speciWc survival, and
progression-free survival rates were 75.1, 45.9, and 42.9%,
respectively. Multivariate analysis showed that recurrent
disease and large tumor volume were independent factors
that predicted poorer disease-speciWc survival. Seventeen
patients developed late complications, including two with
fatal hemorrhage [37]. Severe late complications occurred
in 25% of patients with recurrent NPC. Four percent of
patients with recurrent disease developed massive hemor-
rhage in the nasopharynx after fractionated stereotactic
radiotherapy and died of this complication, and 6% devel-
oped brain stem necrosis [37].
In a study on 125 NPC patients who received salvage
stereotactic radiation Chua et al. [38] compared the results of
stereotactic radiation using single or multiple fractions. All
patients were individually matched for rT stage, and tumor
volume. The median dose was 12.5 Gy in single fraction by
stereotactic radiosurgery, and 34 Gy in 2–6 fractions by frac-
tionated stereotactic radiotherapy. Local control rate was bet-
ter in the last group although overall survival rates were
similar (3-year overall survival rates of 66 and 61%, respec-
tively). Finally, incidence of severe late complications was
33% in the stereotactic radiosurgery group versus 21% in the
fractionated stereotactic radiotherapy group, including brain
necrosis (16 vs. 12%) and hemorrhage (5 vs. 2%) [38].
Radiotherapy with protons
Irradiation with protons instead of the currently used pho-
tons generally results in a signiWcantly lower physical dose
in the co-irradiated healthy tissues, due to its superior beam
properties. In practice, proton beams are typically manipu-
lated to generate a spreadout Bragg peak to yield a Xat
beam depth proWle across the target followed by a rapid fall
to zero dose, thereby producing little or no exit irradiation.
The Bragg peak associated with charged particle beams is
extremely useful when attempting in treating a tumor which
directly overlies vulnerable normal tissue. Although no
clinical data on reirradiation in NPC are available yet,
recent studies comparing dose distribution that can be
achieved with protons compared to photons in NPC indi-
cate superior dose coverage of the target volume with sig-
niWcant better sparing of critical organs [39]. In this regard,
reirradiation using protons may be a very attractive radia-
tion delivery technique for local recurrent NPC.
Table  1 [4, 12, 14, 20, 22,  23, 32, 34] highlights the
results of reirradiation in patients with recurrent NPC.
Role of chemotherapy
DiVerent randomized trials fulWlling strict entry criteria
have compared diVerent regimes of chemoradiotherapy1816 Eur Arch Otorhinolaryngol (2010) 267:1811–1824
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versus radiotherapy alone in patients with primary NPC.
These trials have been summarized in two meta-analysis
studies. Langendijk et al. [10] analyzed 10 randomized
clinical studies including 2,450 patients and found a sur-
vival beneWt of 20% after 5 years, with similar results for
the incidence of local recurrence and distant metastasis. On
the other hand, Chua et al. [40] identiWed two trials with a
total of 784 patients for analysis. The addition of induction
chemotherapy to radiotherapy was associated with a
decrease in relapse by 14.3% and cancer-related deaths by
12.9% at 5 years; however, there was no improvement in
overall survival.
While in early stages local control and overall survival
rates seem similar with or without chemotherapy, this is not
the case for advanced disease. For locally advanced T3–T4
tumors, chemotherapy in conjunction with high cumulative
doses of external beam radiation therapy followed by endo-
cavitary brachytherapy boost; IMRT and/or stereotactic
radiotherapy are the preferred technique for boosting the
primary tumor [41]. Furthermore, in a group of 91 patients,
for stage III–IV tumors the 3-year local control was 86%
and the overall survival was 72% with chemotherapy; they
were 68 and 35% without chemotherapy [42].
It is evident that simultaneous chemoradiation in locally
advanced primary NPCs results in a large survival beneWt.
Nevertheless, the eYcacy of chemotherapy for recurrent
disease, either as the sole treatment or in combination with
radiotherapy is uncertain, and its use has been mainly
reported in recurrent NPC as palliative treatment.
Gebbia et al. [43] reported that use of cisplatin-based
chemotherapy could reach about 65% of tumor response in
recurrent and/or metastatic NPC but the mean survival is
only about 11 months. These results might suggest that the
recurrent NPC be highly responsive to chemotherapy but
survival with chemotherapy alone is poor. It must be
emphasized, however, that in most series there are selection
bias in that most patients given chemotherapy had other
adverse prognostic factors, and chemotherapy is given
either before reirradiation because of a more advanced dis-
ease, or after the retreatment with radiotherapy because of
poor response, but their Wndings do not support the routine
use of chemotherapy [20]. Although diVerent authors have
shown an emerging role for concomitant chemoirradiation
as the primary treatment of local and regionally advanced
NPC, it is uncertain whether it is applicable to retreatment
of purely local recurrences, because the high rates of toxic-
ity and potential complications.
Nasopharyngectomy
Results of surgical treatment and prognostic factors
The role of surgery in the management of malignant tumors
involving the nasopharynx and the infratemporal fossa is
supported by recent reports. The results of removal of
recurrent NPC after radiotherapy failure are encouraging
for T1–T3 tumors, while those patients with T4 stage gen-
erally recur locally or die due to development of metastatic
disease. Nevertheless, 5 patients out of 14 with stage T4 in
the Suárez et al. [44] series were alive, with a follow-up
between 1 and 7 years, but none of them had intracranial
invasion. At variance, all 5 patients with intracranial
involvement died. In other words, the impact on survival of
involvement of diVerent areas in stage T4 is not the same,
the intracranial extension being the worse prognostic factor.
Although some authors have reported encouraging results
in cases of intracavernous involvement [45], surgical sal-
vage of recurrences of NPCs with signiWcant intracranial
extension usually is not justiWed.
Analysis of the literature on nasopharyngectomy depicts
a 30–55% overall 5-year survival, with the largest series
consisting of 60 patients [14, 46–56]. The results of some
of these series are shown in Table 2 [14, 47, 49, 53, 56].
Teo et al. [14] reported on the treatment results of 20
patients with locally recurrent NPC (mostly rT1 and rT2)
Table 1 Results with reirradiation
B brachytherapy, CNS central nervous system, ERT external radiotherapy, SRS stereotactic radiosurgery
Author No. of 
cases
Local 
control (%)
5-year 
survival (%)
Total 
complications (%)
CNS 
complications (%)
Mortality 
(%)
Lee et al. [4] (ERT) 706 32 17 24 6 2
Chang et al. [20] (ERT) 186 12 23 14 0
Hwang et al. [22] (ERT/B/SRS) 64 40 37 45 6 0
Pryzant et al. [12] (ERT) 53 35 21 16 6 10
Teo et al. [14] (ERT) 103 15 8 85 20 3
Leung et al. [23] (ERT/B) 82 38 30 57 29 5
Low et al. [32] (SRS) 36 65 62 44 8 0
Pai et al. [34] (ERT/SRS) 36 40 31 22 0Eur Arch Otorhinolaryngol (2010) 267:1811–1824 1817
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treated with nasopharyngectomy with/without postopera-
tive radiotherapy. This group was compared with other
rT1–T2 patients treated mainly with external radiotherapy
of 60 Gy or greater. Far better local control and survival
was shown for those receiving nasopharyngectomy than
reirradiation. However, 70% of the patients that underwent
surgery also had postoperative radiotherapy due to ques-
tionable and/or unclear resection margins. For the subgroup
that could be treated adequately with nasopharyngectomy
alone, there is a theoretical advantage, as the risk of post-
radiotherapy complications could be minimized.
In contrast, no signiWcant diVerences in overall survival
were observed between a group of 159 patients who
received reirradiation and another group of 22 patients who
underwent nasopharyngectomy with or without postopera-
tive radiotherapy. Salvage surgery was associated with
improved overall survival only in the subgroup with T1 to
T2 local failure, but not in the subgroups with T3 or T4 dis-
ease [57].
Wei et al. [47] reported a 5-year actuarial tumor control
rate of 62%, and a 5-year actuarial disease-free survival rate
of 49% in a series of 60 patients who had a curative resec-
tion.
The importance of postoperative radiotherapy after naso-
pharyngectomy is stressed by King et al. [56], who found a
mean overall survival of 18 months for patients without
postoperative radiotherapy, whereas for patients given post-
operative radiotherapy the mean overall survival was
60 months. However, postoperative irradiation failed to
aVect the prognosis signiWcantly in Hsu et al.’s series [53].
When total resection is achieved local recurrence is not
very common, but in addition postoperative reirradiation is
recommended in patients with positive surgical margins or
advanced stage [46, 47, 52]. If postoperative radiotherapy is
required for positive or uncertain margins, the toxicity may
be compounded and aggravated. Extensive intradural inva-
sion, cavernous sinus involvement and pharyngobasilar fas-
ciae invasion are considered contraindications for surgery
in recurrent NPC [50].
Nasopharyngectomy can be carried out even after a sec-
ond recurrence but given the small number of patients
treated, it is diYcult to make deWnitive conclusions on its
eVectiveness in reirradiated patients. However, it has been
suggested that in appropriately selected patients, the second
course of radiation therapy does not contraindicate surgical
resection, and, in fact, excellent long-term outcome has
been reported. Nevertheless, it increases the morbidity of
the procedure, particularly skull base osteomyelitis, and
great emphasis should be placed on the reconstruction of
the surgical bed, including the use of free Xaps [58].
Analysis of clinical prognostic factors in a series of 53
nasopharyngectomies revealed that margin status, adjuvant
treatment type and parapharyngeal space involvement were
signiWcant impact factors of local control, whereas dura or
brain involvement, local recurrence and adjuvant treatment
type were signiWcant impact factors of survival [59].
According to To et al. [55] all patients who developed
repeat recurrence or died had a high recurrent T-stage
tumor, skull base involvement, multiple recurrences, posi-
tive surgical margins, or concurrent neck node metastasis.
Indications of surgical approaches
A number of anterior and lateral approaches to neoplasms
within the nasopharynx and the infratemporal fossa has
been described [46, 48, 52, 53, 60–62]. It is necessary to
remove all the related structures in the nasopharynx
through a wide approach such as that used in some antero-
lateral approaches, due to the fact that serial whole-organ
section of resected nasopharyngeal specimens showed that
90% of the tumors aVected the eustachian tube cartilage,
and over 90% of the tumors showed extensive submucosal
inWltration [63].
For tumors arising from the nasopharynx and extending
to neighboring regions, such as nasal cavity, maxillary
sinus, sphenoid sinus, and infratemporal fossa, the facial
translocation approach can be the simplest and most direct
way to expose these areas and to facilitate extensive tumor
removal. If the tumor is conWned to the nasopharynx or has
paranasal, retromaxillary or moderate infratemporal exten-
sion, a temporary removal of the anterior, superior and
medial walls of the maxillary sinus will suYce (Fig. 1). The
procedure is carried out with midfacial degloving in order
to avoid facial scars, which in addition allows an excellent
exposure [44, 58, 61, 64, 65]. In extensive tumors of the
nasopharynx and the infratemporal fossa, especially when
Table 2 Results with surgery Author No. of 
cases
Local 
control (%)
5-year 
survival (%)
Total 
complications (%)
Mortality 
(%)
King et al. [56]3 1 5 3 4 7 0
Wei [47]6 0 6 2 4 9 0
Fee et al. [49]3 7 6 7 5 2 5 4 3
Hsu et al. [53]6 0 4 0 3 0 0
Teo et al. [14]2 0 4 0 3 4 01818 Eur Arch Otorhinolaryngol (2010) 267:1811–1824
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the tumor involves the nasal cavity and the posterior wall of
the maxillary sinus, a standard facial translocation approach
is the method of choice, allowing the surgeon a better expo-
sure than that obtained by other infratemporal fossa proce-
dures, such the subtemporal–preauricular approach
(Figs. 2, 3). In this case the procedure is carried out with
midfacial degloving and a hemicoronal–preauricular inci-
sion. When a facial translocation is performed, the possibil-
ity of osteomyelitis or late bone resorption exists [64].
Open standard facial translocation carries very noticeable
sequelae, such as lower lid ectropion, epiphora, medial can-
thus misalignment, nasolacrimal duct obstruction, frontal
muscle palsy, and visible facial scars. Most of these
sequelae, with the exception of nasolacrimal obstruction,
can be avoided with the use of midfacial degloving com-
bined with a hemicoronal preauricular incision that is hid-
den in the hair.
The subtemporal–preauricular approach provides a
direct access to the nasopharynx and related areas, includ-
ing the petrous bone, clivus, infratemporal fossa, retropha-
ryngeal area, apex of the orbit, and the sphenoid and
maxillary sinuses [62,  66] (Figs. 4,  5). This approach is
very versatile, and it may be easily combined with other
skull base procedures in selected cases. When necessary,
additional drilling of the lateral wall of the orbit, the adja-
cent greater wing of the sphenoid on the anterior pole of the
temporal lobe, and the roof of the infratemporal fossa, per-
mits the exposure of extradural tumors involving the Xoor
of the middle fossa [66].
Transoropalatal, mandibular swing, and maxillary swing
approaches are less used now for surgical resection of naso-
pharyngeal lesions. Generally, the transoropalatal approach
is suitable for small tumors centrally located in the midline
position of the nasopharynx because the access to the lat-
eral wall of nasopharynx is restricted. This approach causes
the least injury and does not aVect the face. However, the
surgical exposure is usually not satisfactory.
The mandibular swing approach is suitable in patients
with severe trismus that makes the transoral approach to
access the nasopharynx inadequate or in those patients with
oropharyngeal extension (Fig. 6). Moreover, parapharyn-
geal disease can also be dealt with by this approach. On the
other hand, the surgical Weld is narrow, and secondary
injury is often severe.
Wei et al. [46] adopted an anterolateral approach to the
nasopharynx with the maxilla swung laterally to provide
Fig. 1 a Tumor in the roof of 
the nasopharynx. b Facial 
degloving and osteotomies 
including the anterior, medial 
and lateral walls of the maxillary 
sinus. c Once removed the pos-
terior wall access is gained to the 
nasopharynx and infratemporal 
fossa. d Reposition of removed 
bones at the end of procedureEur Arch Otorhinolaryngol (2010) 267:1811–1824 1819
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adequate exposure of the nasopharynx, having the draw-
back of producing noticeable facial incisions. The posterior
nasal septum can also be removed for better exposure of the
nasopharynx and the paranasopharyngeal space without the
necessity of removing the orbital Xoor. However, the expo-
sure of the nasopharynx is somewhat limited to one side of
the nasopharynx. In addition, the maxillary bone needs to
be freed, and the hard and soft palate have to be split. This
approach can potentially result in destructive complications
such as maxillary necrosis, palate Wstula, and trismus.
Fig. 2 a Axial CT showing an advanced tumor involving the lateral
wall od nasopharynx, infratemporal fossa, pterygoid plates and poster-
ior wall of maxillary sinus. b The coronal CT shows an extension into
the sphenoid sinus. c Postoperative CT after a facial translocation ap-
proach. The anterior maxillary sinus wall and orbito-zygomatic bones
are repositioned and a temporalis muscle Xap Wlls the operative cavity
Fig. 3 Facial translocation 
approach performed through a 
facial degloving and a hemicoro-
nal incision. a Translocated 
facial bones in a single piece. 
b Bilateral facial degloving. 
c Reposition of the anterior 
segment of translocated 
bones. d Reposition of the 
orbito-zygomatic bones and 
part of the temporalis muscle1820 Eur Arch Otorhinolaryngol (2010) 267:1811–1824
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The unsatisfactory surgical exposure and the relatively
high frequency of surgical complications using open tech-
niques led to the development of minimally invasive surgi-
cal methods that overcomes the limitations of conventional
surgery. Currently, use of endoscopic nasopharyngectomy
for tumor resection has been reported for a limited number
of cases. This novel technique has proven to be minimally
invasive and safe for the treatment of recurrent NPC with
encouraging short-term outcomes, but further long-term
follow-up of the patients is required. Thus, Chen et al. [67]
carried out an endoscopic nasopharyngectomy in 37 recur-
rent NPC, almost all of them with rT1–T2 tumors. No
severe complications or deaths resulting from the operation
were observed, with the exception of secretory otitis media,
which occurred in 22% of the cases. The 2-year overall sur-
vival rate, local relapse-free survival rate, and progression-
free survival rate were 84, 86, and 83%, respectively.
Robotic assisted endoscopic nasopharyngeal resection may
play a very important role in these diYcult situations.
Postoperative mortality in all published series is less
than 6%, and generally between 0 and 3% [14, 47, 49, 52,
53, 55, 65]. Death can be caused by massive hemorrhage as
a result of internal carotid artery injury, and intracranial
complications such as meningitis. The most common com-
plications of nasopharyngectomy are palatal Wstula, tris-
mus, otitis media with eVusion, wound infection, skull base
osteomyelitis, and rupture of the internal carotid artery,
with complication rate in up to 50% of patients. Nevertheless,
Fig. 4 DiVerent nasopharyngeal recurrent tumors operated by a sub-
temporal–preauricular approach. a Right lateral wall tumor involving
the infratemporal fossa and skull base extradurally. b Right lateral
wall tumor involving the infratemporal fossa. c Left lateral wall tumor
involving the infratemporal fossa
Fig. 5 Subtemporal–preauricu-
lar approach. a Hemicoronal–
preauricular incision with 
optional neck extension. 
b Exposition of the orbito-zygo-
matic complex before its remov-
al. c The nasopharyngectomy is 
completed. d Reposition of the 
orbito-zygomatic bones and part 
of the temporalis muscleEur Arch Otorhinolaryngol (2010) 267:1811–1824 1821
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postsurgical complications are less in number and severity
than postirradiation ones.
Conclusions
Retreatment of recurrent NPC using radiotherapy, alone or
in combination with other treatment modalities, as well as
surgery, can result in long-term loco–regional control and
survival in a substantial proportion of patients. Treatment
techniques should be highly individualized, and depend on
the site and extent of recurrence, previous treatment, and
the availability of equipment and expertise.
Better local control and survival rates have been shown
for those patients receiving nasopharyngectomy with or
without postoperative radiotherapy than reirradiation in a
signiWcant part of published series. Nevertheless, for small-
volume recurrent tumors (T1–T2) treated with external
radiotherapy, brachytherapy or stereotactic radiosurgery,
comparable results to those obtained with surgery have
been reported. In contrast, treatment results of advanced-
stage locally recurrent NPC are generally more satisfactory
with surgery than with reirradiation (Fig. 7).
The high incidence of major late complications follow-
ing reirradiation is of serious concern. Despite new devel-
opments in technology there is still a high rate of severe
complications following reirradiation, such as brain necro-
sis, cranial nerve palsies, and catastrophic hemorrhages. On
the other hand, the number and severity of complications
following surgery, as well as mortality, is smaller. How-
ever, questionable or unclear resection margins make
necessary the use of postoperative radiotherapy in
patients treated surgically; this may increase morbidity and
adversely aVect the quality of life.
The eYcacy of radiosurgery in the reirradiation of
locally recurrent NPC remains to be established. Although
promising, many published reports on radiosurgery need
Fig. 6 Mandibular swing 
approach. Nasopharyngeal 
recurrence (a) extended to the 
oropharynx (b). c Anterior man-
dibulotomy and approach to the 
oropharynx and nasopharynx. 
d Osteosynthesis of the mandi-
ble
Fig. 7 Guidelines for treatment of recurrent nasopharyngeal cancer
Early diagnosis of recurrence  Late diagnosis of recurrence 
Image Serologic
T1-T2
External beam 
radiotherapy
Gamma-knife
Brachitherapy
Transnasal
endoscopic
approach
T3 T4 Intracranial Paliative
Extracranial
Open surgery
+/- radiotherapy according to margins1822 Eur Arch Otorhinolaryngol (2010) 267:1811–1824
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longer follow-up and frequently this technique has been
used as a boost for external repeated irradiation. Due to its
superior beam characteristics, emerging radiation delivery
techniques such as protons have a high potential to increase
the therapeutic ratio in locally recurrent NPC with
improved local control and/or less toxicity. Endoscopic
resection of recurrent NPC oVers clear advantages with
regard to conventional surgical approaches in terms of mor-
bidity but it lacks long-term follow-up.
Finally, more clinical experiences and trials should be done
in China and South Eastern Asian countries randomizing
T1 + T2 patients to surgery versus radiation therapy compar-
ing outcomes, particularly survival, complications and quality
of life, to address fully the role of surgery and the new tech-
niques of reirradiation in salvaging local failure of NPC.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution Noncommercial License which permits any
noncommercial use, distribution, and reproduction in any medium,
provided the original author(s) and source are credited.
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